BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

  Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer effective February 7, 2022, reporting directly to Eric Shaff, President and Chief Executive Officer.

  February 8, 2022

   · 

  5 min read
• Genetown

  Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference

  Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET.

  February 8, 2022

   · 

  1 min read
• Biotech Bay

  Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

  Bristol Myers Squibb announced $7.965 million in new health equity grants to 24 U.S. non-profit organizations that aim to improve access and quality care to medically underserved patients and communities across oncology, cardiology, immunology and hematology therapeutic areas.

  February 8, 2022

   · 

  4 min read
• Business

  Cytovale Secures Additional BARDA Funding for 10-Minute IntelliSep Test for Sepsis

  Cytovale has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep ™ sepsis risk stratification test towards commercial launch.

  February 8, 2022

   · 

  3 min read
• Business

  Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update

  Sonnet BioTherapeutics Holdings, Inc. announced today its financial results for the three months ended December 31, 2021 and provided a business update.

  February 8, 2022

   · 

  6 min read
• VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

  VectivBio Holding AG today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 1:40 p.m. ET.

  February 8, 2022

   · 

  1 min read
• FDA

  Synthetic Biologics Announces VCN Biosciences’ VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

  Synthetic Biologics, Inc. today announced that VCN Biosciences, S.L.'s VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food & Drug Administration (FDA).

  February 8, 2022

   · 

  6 min read
• ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

  ADC Therapeutics SA today will provide insight into its ADC platform and solid tumor pipeline during a live webcast from 9:00 to 11:00 a.m. EST.

  February 8, 2022

   · 

  3 min read
• Genetown

  Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference

  Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference.

  February 8, 2022

   · 

  1 min read
• Business

  Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

  Appili Therapeutics Inc. announced today it has amended its agreement with Saptalis Pharmaceuticals LLC o expand the territories in which Saptalis will commercialize ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole.

  February 8, 2022

   · 

  5 min read